Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Aikido Pharma Inc, biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics, has secured an early investment in Convergent Therapeutics, Inc. Convergent Therapeutics, Inc. is a startup pharmaceutical company focused on developing next generation radiopharmaceutical therapy for prostate cancer and other applications. Its proprietary technology involves peptide receptor radionuclide therapy (“PRRT”) developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

Background information on Convergent’s Technology

The cornerstone of Convergent’s PRRT technology is its proprietary drug, CONV 01-α, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter. CONV 01-α was specifically designed to bind to the prostate-specific membrane antigen (“PSMA”). A key functional feature of CONV 01-α is that, once bound to PSMA, it internalizes itself and the receptor, delivering its powerful radioactive payload directly into prostate cancer cells. If FDA approved, CONV 01-α would be the first drug approved for an antibody to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in cancer treatment.

Securing this early interest in Convergent Therapeutics, Inc. allows us to continue to follow our mission of developing a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.